Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dactolisib + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Dactolisib (NVP-BEZ235) is a synthetic small molecule of the imidazoquinoline class that acts as a dual inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). It inhibits the catalytic subunit p110α of PI3K by competing at its ATP binding site and also inhibits mTOR activity. Paclitaxel is a microtubule-stabilizing cytotoxic agent that causes mitotic arrest leading to cell death. The combination has been investigated in preclinical and clinical studies for enhanced antitumor efficacy in various solid tumors, including breast cancer and gastric cancer. Dactolisib may sensitize tumors to paclitaxel by inhibiting PI3K/mTOR pathway activation associated with taxane resistance[1][2][5][6].
- Other names
- BEZ235 + paclitaxel
02
Targets
mTOR (Mammalian target of rapamycin kinase)PIK3CA (Phosphoinositide 3-kinase alpha)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on dactolisib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dactolisib + paclitaxel.